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2571center (STAR technique was used in only 5% of 1,035 CTO
patients). It is obvious that this technique cannot be confused with
other techniques of anterograde or retrograde CTO percutaneous
coronary intervention (PCI) that include intended limited dissec-
tion such as the CART, the reverse CART, or re-entry using the
BridgePoint device (BridgePoint Medical/Boston Scientiﬁc, Min-
neapolis, Minnesota).
The statement that in our study only one-half of the STAR
technique patients underwent angiographic follow-up is
misleading: angiography was performed in 28 of the 34 patients
with successful STAR technique (82% follow-up rate).
Your statement “In summary, a predominantly antegrade wire-
based strategy of CTO-PCI is associated with low success rates”
cannot be shared because the large majority of CTO PCIs are
performed using an anterograde approach, and the success rate in
a high-volume center is largely >80%.
Finally, we like to add that the main ﬁnding of the study was not
considered by Dr. Kandzari and colleagues: the everolimus-eluting
stent was associated with a dramatic decrease in the risk of reoc-
clusion compared with ﬁrst-generation drug-eluting stents (odds
ratio: 0.22). Dr. Kandzari and colleagues refer to an ongoing study
that will provide “more detailed clinical outcomes speciﬁc to these
methods” (NCT01435031): this study is a sponsored registry
(Abbott Vascular) that will include 250 patients over a period of 33
months, the aim of which is the assessment of the performance of
the sponsor devices (Xience stent, Progress wire, Mini-Trek
catheter) in CTO. The study design does not include angio-
graphic follow-up. We hope that with regard to the clinical
performance of the everolimus-eluting stent, the result of the study
will conﬁrm the results of our studies (1,2) despite the smaller
number of patients and the very long planned enrollment period.Renato Valenti, MD
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A Villain or a Decent Actor in the
Process of Ongoing Myocardial Injury?
In a recent issue of the Journal, Popp (1) reviewed the modern
techniques to measure cardiac troponin (cTn) and the value ofincreased cTn as a marker of myocardial injury and predictor of
future heart failure. More importantly, we have read and agree with
the author’s hypothesis: “cTn.to be an actor in this process of
ongoing myocardial injury and not simply a messenger of that
injury.” However, our next question is whether the actor is a villain
or decent.
Myocardial cell injuries that are caused by severe myocardial
ischemia can lead to the persistent release of cTn, which results in
a sustained increase in the peripheral circulation. During this
process, many types of cells, including cardiomyocytes and
immunocytes, are exposed to high concentrations of cTn in the
extracellular ﬂuid. Several studies have found that long-term
exposure of the immune system to cTn I can elicit an immune
response and produces anti-cTn antibodies, which in turn produce
serious cardiac inﬂammation and overt cardiac dysfunction (2,3).
However, we need to consider the direct effects of high-level cTn
on surrounding surviving cardiomyocytes after severe ischemia. Our
previous study demonstrated that during short-term myocardial
hypoxia/reoxygenation (48 h in total), the exogenous cTn I reduces
myocardial cell injuries and preserves the metabolic activity of
myocardial cells in vitro and that the protective effect is attributed
to the activity of cTn I and is dose dependent (4). Although the
underlying mechanisms of this protective effect are unclear, it
remains reasonable to propose the possibility that cTn has various
facets in the different stages during the process of myocardial
injury, just as heat shock protein-60, in the initial stages of stress, is
primarily responsible for maintaining the integrity of cellular
proteins, and is likely to induce autoimmune reactions to potentiate
the progressive process of atherosclerosis (5). At the beginning of
ischemia, a feedback response to the released cTn is initiated to
prevent further acute myocardial cell damage, but afterward, the
presence of anti-cTn autoantibodies is involved in the ongoing
myocardial damage. Accordingly, further studies are warranted to
see the true colors of cTn in the different stages during the ongoing
process of myocardial injury.Yong Peng, MD
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thrombosis. J Thromb Haemost 2009;7:710–9.ReplyThe letter from Dr. Peng and colleagues calls attention to their
previous article reporting a graded protective effect of cardiac
troponin (cTn) at high concentrations on isolated neonatal rat
myocardial cells subjected to hypoxia. This suggests that cTn may
be an “actor” at the time of acute myocellular injury, with a beneﬁcial
effect, and not simply a “messenger” of the acute damage. They
endorse the premise that cTn may have a role in later, or ongoing,
myocardial injury (1). Heat shock protein-60 apparently has
a “good” inﬂuence in an acute situation and a “bad” effect via
autoimmune mechanisms in the long term (2). This example may be
another cogent analogy to the mechanism that I proposed for cTn.
I appreciate both their comments and their participation in what
hopefully will be an ongoing investigation by many in the research
community. We need to better understand the possible role of cTn
and other proteins related to myocardial injury in the currentlyopaque path leading from initial myocardial insult to cardiac
dysfunction months to years later.*Richard L. Popp, MD
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